SCHEMBL6237159

SCHEMBL6237159

COc1cc(OC)c2cc(C(=O)NN)oc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.50
ALDH1A1 P00352 4/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 3/20 0.50
GLA P06280 1/20 0.50
CYP3A4 P08684 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GAA P10253 2/20 0.46
TP53 P04637 2/20 0.44
MAOB P27338 1/20 0.44
MAPT P10636 1/20 0.43
TAS1R3 Q7RTX0 5/20 0.43
TAS1R1 Q7RTX1 5/20 0.43
CYP2D6 P10635 1/20 0.42
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ACHE P22303 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26323655 0.84 GAA (0.43) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL6241919 0.83 ALDH1A1 (0.60) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL4600109 0.83 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL26323917 0.82 ALDH1A1 (0.41) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL15349547 0.81 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL24522290 0.80 AKR1B1 (0.50) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL5585274 0.79 HTT (0.54) KDM4EALDH1A1L3MBTL1GAAMAPT
SCHEMBL7277876 0.77 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL7277881 0.75 GAA (0.49) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL6240000 0.75 CYP2D6 (0.70) KDM4EALDH1A1HPGDHSD17B10GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206857-B Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions comprising the same 韩国生命工学研究院 2024-09-06 CN disclosed
US-20230293487-A1 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2023-09-21 US disclosed
EP-4186503-A1 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES Korea Research Institute of Bioscience and Biotechnology (KR) 2023-05-31 EP disclosed
CN-116157120-A Anti-inflammatory compositions comprising benzofuranyl N-acylhydrazone derivatives 韩国生命工学研究院 2023-05-23 CN disclosed
EP-4015516-A1 BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Korea Research Institute of Bioscience and Biotechnology (KR) 2022-06-22 EP disclosed
CN-114206857-A Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions containing the same 韩国生命工学研究院 2022-03-18 CN disclosed
EP-1320523-B1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER LAMBERT CO (US) 2005-06-22 EP disclosed
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY LLC 2005-01-06 US disclosed
EP-1320523-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Warner-Lambert Company LLC (US) 2003-06-25 EP disclosed
WO-2002024672-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases BCAT1, BCAT2, ABAT KDM4E 3961/4885ALDH1A1 642/4885HPGD 2276/4885
US-20230293487-A1 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES RELA, NFKBIA, IKBKG KDM4E 2006/4885ALDH1A1 1094/4885HPGD 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.